Story perspectives

New Schizophrenia Treatment X-T Offers Hope Without Side Effects

7/13/2025

43 5

Summary

Story summary

At the 2025 Southern California Psychiatry Conference, researchers unveiled xanomeline-trospium (X-T) as a groundbreaking treatment for schizophrenia. This innovative therapy, which focuses on cholinergic pathways rather than traditional dopamine blockers, has demonstrated remarkable symptom relief without the risk of tardive dyskinesia. While FDA-approved as a standalone treatment, it necessitates vigilant monitoring, especially for those on other antipsychotics.

1 of 1

Story summary

At the 2025 Southern California Psychiatry Conference, researchers unveiled xanomeline-trospium (X-T) as a groundbreaking treatment for schizophrenia. This innovative therapy, which focuses on cholinergic pathways rather than traditional dopamine blockers, has demonstrated remarkable symptom relief without the risk of tardive dyskinesia. While FDA-approved as a standalone treatment, it necessitates vigilant monitoring, especially for those on other antipsychotics.